C WorldWide Group Holding A S Buys 26,169 Shares of Edwards Lifesciences Co. (NYSE:EW)

C WorldWide Group Holding A S boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 5.5% during the fourth quarter, Holdings Channel reports. The fund owned 505,565 shares of the medical research company’s stock after acquiring an additional 26,169 shares during the period. Edwards Lifesciences comprises 0.5% of C WorldWide Group Holding A S’s holdings, making the stock its 22nd biggest holding. C WorldWide Group Holding A S’s holdings in Edwards Lifesciences were worth $38,549,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in EW. Martin Capital Advisors LLP boosted its stake in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after purchasing an additional 128 shares in the last quarter. Legacy Wealth Asset Management LLC boosted its position in Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares during the period. DMC Group LLC grew its stake in shares of Edwards Lifesciences by 4.5% during the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock valued at $272,000 after buying an additional 154 shares during the last quarter. Granite Harbor Advisors Inc. increased its holdings in shares of Edwards Lifesciences by 4.2% in the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after buying an additional 155 shares during the period. Finally, Stableford Capital II LLC lifted its stake in shares of Edwards Lifesciences by 2.7% in the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock valued at $449,000 after acquiring an additional 155 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $1.58 during trading on Friday, hitting $86.43. 4,979,943 shares of the company’s stock traded hands, compared to its average volume of 2,883,164. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The business has a 50-day simple moving average of $90.28 and a 200-day simple moving average of $78.85. The stock has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a PEG ratio of 4.36 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at $388,801.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $388,801.62. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday. Evercore ISI cut their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $93.33.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.